September 20, 2022

Phase 2 Trial Hints at Promise of Cellular Therapy for Progressive MS

Single-arm, open-label study offers proof of concept for MSC-NTF cells

22-NEU-3222062_mesenchymal-stem-cells_650x450

In patients with progressive multiple sclerosis (MS), accumulating central nervous system injury leads to damage of both white and gray matter in the brain. The result is functional impairments for which no effective reparative therapies are currently available.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

New findings from a phase 2 study provide preliminary evidence on the safety and potential efficacy of using autologous mesenchymal stem cells that secrete neurotrophic factors (MSC-NTF cells) to treat patients with progressive MS. The results from the study, published online in Multiple Sclerosis Journal, reflect experience in a small population in an open-label setting without a placebo group.

“The efficacy data offer promising biological and clinical signals of a treatment effect, but because of the lack of a comparator group, they should be interpreted with caution,” says lead author Jeffrey Cohen, MD, Director of the Experimental Therapeutics Program in Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research. “These preliminary results need to be confirmed in a placebo-controlled trial.”

The cellular therapy at a glance

MSC-NTF cells are produced from autologous, bone marrow-derived MSCs that are expanded and differentiated in culture. The MSCs are converted into MSC-NTF cells by cultivating them under conditions that induce secretion of high levels of NTFs and immunomodulatory cytokines. Successful evaluation of MSC-NTF in animal models relevant to progressive MS led to initial assessment in humans, with intrathecal administration eventually chosen to enable direct delivery of NTFs to the central nervous system.

Study design

The phase 2 study was conducted from March 2019 to March 2021 at four U.S. academic centers, including Cleveland Clinic. Twenty adults were enrolled, all of whom had primary/secondary progressive MS, no relapse 6 months prior to screening, a baseline Expanded Disability Status Scale (EDSS) score of 3.0 to 6.5, and a timed 25-foot walk speed (T25FW) of ≤ 60 seconds.

Participants were allowed to continue taking a stable dose of an approved disease-modifying therapy. After a pretreatment period of approximately 10 weeks during which the cells were cultured, autologous MSC-NTF cells were administered intrathecally at weeks 0, 8 and 16, followed by a 12-week post-treatment observation period.

Eighteen participants (10 women, eight men) with a mean EDSS score of 5.4 ± 1.3 and a mean age of 47.4 ± 9.6 years ultimately were treated with MSC-NTF cells. Seventeen received all three treatments, and one received two treatments.

Advertisement

Safety findings

The primary endpoint was safety, assessed in terms of incidence of treatment-emergent adverse events (TEAEs) and clinically relevant changes in vital signs, need for concomitant medications, clinical laboratory assessments and physical/neurologic testing. T2 lesion status at baseline and at study’s end was evaluated with brain MRI.

No deaths or adverse events related to worsening of MS occurred, and no clinically significant changes in safety lab results or vital signs were reported.

During the study, two patients developed symptoms of low back and leg pain accompanied by characteristic clumping of lumbar nerve roots on MRI, consistent with arachnoiditis. In both patients, symptoms developed after one of the three intrathecal treatments. In one patient, the symptoms occurred after the second treatment and resolved after administration of epidural cortisone injections and analgesics, which enabled completion of the third treatment with no complications. In the second patient, the apparent arachnoiditis occurred after the third intrathecal administration and did not fully resolve with treatment.

Two study participants were hospitalized for serious TEAEs. One was the second patient with arachnoiditis noted above, who withdrew from the study. The other reported nonspecific symptoms — anxiety and dizziness that led to study withdrawal — after their second treatment.

No other safety signals were seen, and there was no change in brain T2 lesion volume or count in brain FLAIR MRI measures over 28 weeks to suggest disease activation.

Efficacy findings

Clinical response was prespecified as an improvement of ≥ 25% from baseline (considered a clinically meaningful change) in the T25FW or the 9-hole peg test at week 28. Efficacy was also assessed in terms of improvement in scores on the EDSS, the Symbol Digit Modalities Test (SDMT), the low-contrast letter acuity test (LCLA) and the 12-item Multiple Sclerosis Walking Scale (MSWS-12). The efficacy outcomes in study participants were compared with those of a prespecified matched group of 48 patients with progressive MS from the CLIMB Study registry.

Advertisement

Clinical response was achieved by 19% of study participants compared with 4% of matched CLIMB registry patients. Additionally, from 27% to 67% of study participants showed clinically meaningful improvements from baseline in scores on the LCLA, MSWS-12 and SDMT; no patients with a baseline EDSS score ≤ 5.5 showed improvement ≥ 1.0, although 30% of patients with a baseline EDSS score > 5.5 showed improvement ≥ 0.5.

Additionally, treatment consistently resulted in increases in cerebrospinal fluid neuroprotective factors (VEGF-A, HGF, NCAM-1, follistatin, LIF and fetuin-A) as well as reductions in inflammatory biomarkers (MCP-1, sCD27, SDF-1 and osteopontin).

Bottom line: Intriguing but preliminary

“The combined activity of MSC-NTF cells in immunomodulation and neuroprotection may be relevant to progressive MS,” says Dr. Cohen, “and intrathecal delivery of the therapy may offer an advantage by directly addressing compartmentalized inflammation and/or failure of neuroprotective mechanisms. It is not possible, however, to extrapolate observations in this study to patients with progressive MS experiencing clinical or MRI disease activity. We look forward to further studies of this interesting therapeutic approach.”

The study was funded by Brainstorm Cell Therapeutics, which is developing the MSC-NTF cell therapy.

Related Articles

histology image of a gray matter lesion in a multiple sclerosis brain
March 4, 2024
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

illustration of a neuron affected by multiple sclerosis
February 29, 2024
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

22-NEU-3087358_pediatric-multiple-sclerosis_650x450
September 27, 2022
Making Pediatrics More of a Priority in Multiple Sclerosis Treatment Trials

New review makes the case for earlier pediatric enrollment and other changes

photo of doctor performing neurologic exam on a patient
August 11, 2023
A New Guide to the Differential Diagnosis of Multiple Sclerosis

Updated consensus approach helps clinicians efficiently improve diagnostic accuracy

23-NEU-4060108_pregnancy-care-visit_650x450
July 27, 2023
Reproductive Issues and Multiple Sclerosis: 20 Frequently Asked Questions

The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed

23-NEU-3813861 multiple-sclerosis-patient_650x450
July 24, 2023
How the SPRINT-MS Follow-On Study Aims to Enhance Future Trials of Progressive Multiple Sclerosis

In search of optimal imaging biomarkers, best methods for long-term follow-up

23-NEU-3991918 CQD hero_650x450
June 26, 2023
For Older Patients With Multiple Sclerosis, Discontinuing Disease-Modifying Therapy May Be an Option

Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy

23-NEU-3839389-CQD-Hero-650×450
May 24, 2023
DELIVER-MS Trial Extended to Guide Philosophy for Long-Term Multiple Sclerosis Therapy

$1.1M award expands follow-up to six years with focus on clinical endpoints

Ad